Blood sampling, skin biopsy, excreta sampling, lumbar puncture
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neurodegenerative Diseases
Conditions
Neurodegenerative Diseases
Trial Timeline
Sep 1, 2024 → Aug 31, 2034
NCT ID
NCT06516016About Blood sampling, skin biopsy, excreta sampling, lumbar puncture
Blood sampling, skin biopsy, excreta sampling, lumbar puncture is a pre-clinical stage product being developed by Brain Biotech for Neurodegenerative Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06516016. Target conditions include Neurodegenerative Diseases.
What happened to similar drugs?
1 of 4 similar drugs in Neurodegenerative Diseases were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
3
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06516016 | Pre-clinical | Recruiting |
Competing Products
5 competing products in Neurodegenerative Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Latozinemab | Alector | Phase 3 | 22 |
| ONO-2808 + Placebo | Ono Pharmaceutical | Phase 1 | 29 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 3 | 37 |
| Pimavanserin | Acadia Pharmaceuticals | Approved | 47 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 37 |